睿知中国医院研究地图
候选清单

正在招募肝细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

JMT106 Injection in the Treatment of Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07275073,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed advanced solid tumor.

    入选标准第 2 条

  3. NYHA class ≥II or LVEF <50%;

    排除标准第 22 条

  4. Previous treatment with anti-GPC3 therapy.

    排除标准第 1 条

    Grade ≥3 immune-related adverse events (irAEs, per CTCAE 5.0) from prior immunotherapy.

    排除标准第 6 条

  5. ECOG performance status of 0-1.

    入选标准第 5 条

  6. Absolute neutrophil count (ANC) ≥1.5×10⁹/L;

    入选标准第 8 条

    Platelets (PLT) ≥90×10⁹/L;

    入选标准第 9 条

    Hemoglobin (Hb) ≥90 g/L;

    入选标准第 10 条

    Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for liver metastases or hepatocellular carcinoma);

    入选标准第 11 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for liver metastases or hepatocellular carcinoma);

    入选标准第 12 条

    Creatinine clearance (Ccr) >50 mL/min (calculated by Cockcroft-Gault formula);

    入选标准第 13 条

    Activated partial thromboplastin time (APTT) ≤1.5×ULN; INR ≤1.5×ULN.

    入选标准第 14 条

  7. At least one measurable lesion according to RECIST 1.1 criteria.

    入选标准第 4 条

  8. Active bacterial, fungal, or viral infection requiring IV treatment within 14 days before randomization (prophylactic therapy allowed if no active infection symptoms); patients with viral hepatitis are allowed to receive antiviral treatment.

    排除标准第 11 条

    Immunodeficiency, including HIV-positive status.

    排除标准第 14 条

    HBsAg-positive or HBcAb-positive with HBV-DNA >2000 IU/mL; HCV antibody-positive with HCV-RNA positivity.

    排除标准第 15 条

    History of tuberculosis treatment within 2 years before the first dose.

    排除标准第 16 条

    Other active malignancies within 2 years (except cured localized tumors, e.g., basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, in situ prostate/cervical/breast cancer).

    排除标准第 25 条

  9. Fertile participants (male and female) must agree to use reliable contraception (hormonal, barrier, or abstinence) with their partners during the trial and for at least 180 days after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment.

    入选标准第 15 条

    Pregnancy or lactation.

    排除标准第 27 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07275073,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years.
  2. Histologically or cytologically confirmed advanced solid tumor.
  3. Failure of at least one line of standard therapy, or no standard treatment available, or intolerant to standard treatment at the current stage.
  4. At least one measurable lesion according to RECIST 1.1 criteria.
  5. ECOG performance status of 0-1.
  6. Expected survival ≥3 months.
  7. Sufficient organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factor treatment within 14 days):
  8. Absolute neutrophil count (ANC) ≥1.5×10⁹/L;
  9. Platelets (PLT) ≥90×10⁹/L;
  10. Hemoglobin (Hb) ≥90 g/L;
  11. Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for liver metastases or hepatocellular carcinoma);
  12. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for liver metastases or hepatocellular carcinoma);
  13. Creatinine clearance (Ccr) >50 mL/min (calculated by Cockcroft-Gault formula);
  14. Activated partial thromboplastin time (APTT) ≤1.5×ULN; INR ≤1.5×ULN.
  15. Fertile participants (male and female) must agree to use reliable contraception (hormonal, barrier, or abstinence) with their partners during the trial and for at least 180 days after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment.
  16. Understand and voluntarily sign the informed consent form (ICF).

排除标准:Exclusion Criteria:

  1. Previous treatment with anti-GPC3 therapy.
  2. Presence of spinal cord compression or clinically active central nervous system metastases (untreated or symptomatic metastases, or those requiring corticosteroids/anticonvulsants for symptom control), or carcinomatous meningitis. Patients with previously treated brain metastases (e.g., whole-brain radiotherapy or stereotactic brain radiotherapy) may be enrolled if clinically stable for ≥4 weeks with no imaging evidence of progressive brain metastases.
  3. Long-term immunosuppressive therapy (e.g., cyclosporine) or daily systemic steroid therapy (e.g., >20 mg prednisone or equivalent), excluding those using nasal spray, inhaled, or other topical glucocorticoid therapies.
  4. Adverse reactions from prior antitumor therapy not recovered to CTCAE 5.0 Grade ≤1 (excluding toxicities deemed non-risky by the investigator, e.g., alopecia).
  5. Any antitumor therapy (chemotherapy, targeted therapy, immunotherapy, etc.) or investigational intervention within 4 weeks or 5 half-lives (whichever is shorter) before the first dose, or traditional Chinese medicine with antitumor indications within 14 days prior.
  6. Grade ≥3 immune-related adverse events (irAEs, per CTCAE 5.0) from prior immunotherapy.
  7. Concurrent participation in another interventional clinical trial (observational trials or follow-up phases allowed).
  8. Major surgery within 28 days before the first dose or planned tumor resection during the study.
  9. Significant bleeding tendency within 4 weeks before the first dose, or high-risk conditions (e.g., gastrointestinal hemorrhage, severe hemoptysis) per investigator judgment; hereditary bleeding disorders.
  10. Known severe allergy to the study drug or its excipients.
  11. Active bacterial, fungal, or viral infection requiring IV treatment within 14 days before randomization (prophylactic therapy allowed if no active infection symptoms); patients with viral hepatitis are allowed to receive antiviral treatment.
  12. Uncontrolled effusions (pleural, peritoneal, pericardial) requiring frequent drainage or intervention within 14 days before the first dose (excluding cytologic evaluation of effusions).
  13. History of allogeneic organ or hematopoietic stem cell transplantation.
  14. Immunodeficiency, including HIV-positive status.
  15. HBsAg-positive or HBcAb-positive with HBV-DNA >2000 IU/mL; HCV antibody-positive with HCV-RNA positivity.
  16. History of tuberculosis treatment within 2 years before the first dose.
  17. Interstitial lung disease or severe pulmonary dysfunction.
  18. History of inflammatory bowel disease or chronic diarrhea.
  19. Severe cardiovascular/cerebrovascular disease, including:
  20. Severe arrhythmias/conduction abnormalities (e.g., ventricular arrhythmias requiring intervention, AV block grade II-III);
  21. Acute coronary syndrome, congestive heart failure, stroke, or other Grade ≥3 cardiovascular events within 6 months before the first dose;
  22. NYHA class ≥II or LVEF <50%;
  23. Long QTc syndrome or QTc >480 ms (Fridericia formula), or concomitant use of QTc-prolonging drugs;
  24. Uncontrolled hypertension (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg at screening).
  25. Other active malignancies within 2 years (except cured localized tumors, e.g., basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, in situ prostate/cervical/breast cancer).
  26. Live vaccination within 28 days before the first dose (inactivated vaccines, e.g., seasonal flu vaccine, allowed).
  27. Pregnancy or lactation.
  28. Other conditions deemed unsuitable by the investigator (e.g., depression history/current treatment, psychiatric disorders affecting compliance, main portal vein tumor thrombus).

引自 ClinicalTrials.gov, NCT07275073, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07275073,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07275073